1. Acadia Pharmaceuticals will host an R&D day in NYC on June 25, 2025. 2. The event will discuss their pipeline for neurological and rare diseases. 3. Key opinion leaders and management will present at the event. 4. Acadia is advancing treatments for conditions like Parkinson’s and Rett syndrome. 5. They focus on several clinical-stage programs targeting neuro-rare diseases.
The R&D day suggests strong forward momentum in Acadia's pipeline, potentially increasing investor confidence and interest. Similar events in biotech often lead to price appreciation, particularly if promising data is shared.
The focus on their innovative pipeline enhances ACAD's growth prospects, making this announcement particularly important for investors.
The information revealed at the R&D day could affect investor sentiment and company valuation significantly over the longer term as clinical developments progress.
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET.
The event will feature members of Acadia’s management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community.
To register for the live webcast, please click here. A replay of Acadia’s R&D Day will be available on the company’s website, acadia.com, under the investors section for approximately 3 months following the event.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at acadia.com and follow us on LinkedIn and X.